Informações:
Falhas:
ID
34177
Descrição
Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers; ODM derived from: https://clinicaltrials.gov/show/NCT02098954
Link
https://clinicaltrials.gov/show/NCT02098954
Palavras-chave
Versões (1)
- 15/01/2019 15/01/2019 -
Titular dos direitos
GSK group of companies
Transferido a
15 de janeiro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 3.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Carcinoma, Non-Small Cell Lung NCT02098954
Eligibility Carcinoma, Non-Small Cell Lung NCT02098954
- StudyEvent: Eligibility
Similar models
Eligibility Carcinoma, Non-Small Cell Lung NCT02098954
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
ID.1
Item
advanced non-small cell lung cancer, stage iiib/iv
boolean
ID.2
Item
non-squamous
boolean
ID.3
Item
egfr sensitive mutations, such as exon 19 del, or exon 21 l858r
boolean
ID.4
Item
received first line tkis treatment and developed tki resistance
boolean
ID.5
Item
ecog 0-2
boolean
ID.6
Item
squamous non-small cell lung cancer
boolean
ID.7
Item
patients have unstable brain metastasis, predict survival less than 8 weeks
boolean
ID.8
Item
spinal-cord compression without evidence of stabilisation or treatment
boolean
ID.9
Item
women who were pregnant or lactating; women with a positive or no available pregnancy test result at baseline
boolean
ID.10
Item
patients have any unstable illness that could not receive further treatment
boolean